Lisata Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a modest revenue of $70,000, attributed to an upfront license fee from a research agreement. This marks a significant change from the same period in 2024, when the company reported no revenue. The net loss for the quarter was $4.7 million, a decrease from the $5.0 million loss reported in the prior year, indicating a reduction in operational expenses.
Total operating expenses for the second quarter of 2025 were approximately $4.9 million, down from $5.5 million in the same quarter of 2024, reflecting a 10.6% decrease. This reduction was primarily driven by lower research and development costs, which fell to $2.3 million from $2.6 million, and a decrease in general and administrative expenses, which declined to $2.7 million from $2.9 million. The company attributed these savings to reduced patient treatment costs and lower spending on clinical research organization services.
For the first half of 2025, Lisata reported a net loss of $9.4 million, compared to a loss of $10.4 million for the same period in 2024. Operating expenses for the six months ended June 30, 2025, totaled $10.8 million, down from $12.1 million in the previous year. The company continues to focus on its investigational product, certepetide, which is currently undergoing several Phase 2 clinical trials for various solid tumors, including metastatic pancreatic ductal adenocarcinoma.
Lisata's cash, cash equivalents, and marketable securities stood at approximately $22.0 million as of June 30, 2025. The company reported a net cash used in operating activities of $9.4 million for the first half of 2025, a decrease from $12.3 million in the same period of 2024. The company anticipates that its current cash reserves will be sufficient to meet its operational needs for at least the next 12 months, although it may require additional financing by late 2026 to support its long-term liquidity needs.
Looking ahead, Lisata Therapeutics is focused on advancing its clinical programs and exploring potential partnerships to enhance its product pipeline. The company remains committed to addressing unmet medical needs in oncology and is actively seeking opportunities for collaboration and funding to support its research and development efforts.
About LISATA THERAPEUTICS, INC.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.